Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pegpleranib - IVERIC bio

Next Previous
Search
Drug Profile

Pegpleranib - IVERIC bio

Alternative Names: E-10030; E01AJ; Fovista; OAP-030; Pegpleranib sodium; X01E

Latest Information Update: 13 Jul 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Archemix Corporation
  • Developer IVERIC bio; National Eye Institute
  • Class Eye disorder therapies; Oligonucleotides; Peptide aptamers
  • Mechanism of Action Angiogenesis inhibitors; Platelet-derived growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Retinoblastoma; Von Hippel-Lindau disease; Wet age-related macular degeneration

Most Recent Events

  • 11 Jul 2023 IVERIC bio has been acquired by Astellas Pharma
  • 16 Apr 2019 Ophthotech Corporation is now called IVERIC bio
  • 14 Aug 2017 Efficacy and adverse events data from a phase III OPH 1004 trial in Wet age-related macular degeneration released by OphthoTech

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top